U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07350577) titled 'Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants' on Dec. 01, 2025.
Brief Summary: This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
Study Start Date: Nov. 17, 2025
Study Type: INTERVENTIONAL
Condition:
Ulcerative Colitis (UC)
Intervention:
BIOLOGICAL: ALTB-268
monoclonal antibody
OTHER: Placebo
Saline solution
Recruitment Status: RECRUITING
Sponsor: AltruBio Inc.
Published by HT Digital Content Services with perm...